{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:31:58Z","timestamp":1724668318912},"reference-count":16,"publisher":"Cambridge University Press (CUP)","issue":"3","license":[{"start":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T00:00:00Z","timestamp":1454371200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir. j. psychol. Med."],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:sec id=\"S0790966715000713_abs1\" sec-type=\"intro\"><jats:title>Introduction<\/jats:title><jats:p>Mirtazapine is indicated in the treatment of major depressive disorder particularly in selective serotonin re-uptake inhibitors resistance. Its effect on hair loss is rare with no previous documented effect on hair colour.<\/jats:p><\/jats:sec><jats:sec id=\"S0790966715000713_abs2\" sec-type=\"general\"><jats:title>Method<\/jats:title><jats:p>Review of relevant literature and description of a case report of a 54-year-old male patient who developed alopecia and hair discoloration after initiation of mirtazapine treatment.<\/jats:p><\/jats:sec><jats:sec id=\"S0790966715000713_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Upon cessation of mirtazapine treatment full restoration of hair colour and regrowth of hair was attained within 10 weeks.<\/jats:p><\/jats:sec><jats:sec id=\"S0790966715000713_abs4\" sec-type=\"discussion\"><jats:title>Discussion<\/jats:title><jats:p>There was clear temporal relationship between experiencing hair loss and commencing mirtazapine treatment. No other more likely medical reason to explain such experience was established. A noticeable restoration of the hair colour occurred following mirtazapine cessation.<\/jats:p><\/jats:sec><jats:sec id=\"S0790966715000713_abs5\" sec-type=\"conclusion\"><jats:title>Conclusion<\/jats:title><jats:p>Mirtazapine is associated with hair discoloration and hair loss. The possibility of such distressing adverse effects needs to be conveyed to patients by clinicians and to be further explored by researchers.<\/jats:p><\/jats:sec>","DOI":"10.1017\/ipm.2015.71","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T04:59:32Z","timestamp":1454389172000},"page":"175-178","source":"Crossref","is-referenced-by-count":3,"title":["Psychiatric shades of grey: mirtazapine-induced hair discoloration and hair loss"],"prefix":"10.1017","volume":"33","author":[{"given":"M.","family":"Osman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. D.","family":"McCauley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2016,2,2]]},"reference":[{"key":"S0790966715000713_ref9","doi-asserted-by":"publisher","DOI":"10.3109\/10401230009147085"},{"key":"S0790966715000713_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2008.12.005"},{"key":"S0790966715000713_ref11","first-page":"155pp","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2012"},{"key":"S0790966715000713_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.micron.2003.11.006"},{"key":"S0790966715000713_ref14","first-page":"990","article-title":"Ziekenhuisapotheek Medisch Centrum Leeuwarden\/Apotheek Ziekenhuis De Tjongerschans Heerenveen [Drug induced alopecia]","volume":"143","author":"van den Bemt","year":"1999","journal-title":"Nederlands Tijdschrift Voor Geneeskunde"},{"key":"S0790966715000713_ref7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10l06015blu"},{"key":"S0790966715000713_ref3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.neuropsych.23.1.E7"},{"key":"S0790966715000713_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328330adb2"},{"key":"S0790966715000713_ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.1992.tb01307.x"},{"key":"S0790966715000713_ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm0912609"},{"key":"S0790966715000713_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)11381-3"},{"key":"S0790966715000713_ref8","first-page":"145","article-title":"Drug-induced alopecia: review of the literature","volume":"50","author":"Llau","year":"1995","journal-title":"Therapie"},{"key":"S0790966715000713_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.02.030"},{"key":"S0790966715000713_ref1","first-page":"256pp","volume-title":"British National Formulary (2014)"},{"key":"S0790966715000713_ref13","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199410040-00005"},{"key":"S0790966715000713_ref16","first-page":"CD006528","article-title":"Mirtazapine versus other antidepressive agents for depression","volume":"7","author":"Watanabe","year":"2011","journal-title":"Cochrane Database Systematic Reviews"}],"container-title":["Irish Journal of Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0790966715000713","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,18]],"date-time":"2019-04-18T20:03:54Z","timestamp":1555617834000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0790966715000713\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,2]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0790966715000713"],"URL":"https:\/\/doi.org\/10.1017\/ipm.2015.71","relation":{},"ISSN":["0790-9667","2051-6967"],"issn-type":[{"value":"0790-9667","type":"print"},{"value":"2051-6967","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,2]]}}}